Overview
Adult RSV vaccination decisions are shifting from a single age threshold toward two CDC paths: one dose for all adults aged 75 years or older, and increased-risk consideration for adults aged 50–74. The series explains why hospitalization and severe-outcome prevention matter, how a two-season hospitalized IVY study estimated protection, and why average effectiveness does not predict every person’s benefit. It examines subgroup variation, possible but unconfirmed waning, uneven product evidence, practical timing, and the FDA’s product- and population-specific GBS signal. The value is a calibrated framework, not a personal risk score or annual booster rule.
Learning outcomes
- CDC recommends one RSV vaccine dose for adults aged 75 years or older and for adults aged 50–74 at increased risk of severe RSV illness.
- Across two seasons, one dose was associated with 58% effectiveness against RSV-associated hospitalization in adults aged 60 years or older; this was an observational population estimate, not a personal guarantee.
- Higher baseline risk can preserve meaningful absolute benefit even when relative effectiveness is lower or less precise in a subgroup.
- Same-season effectiveness estimates were higher than prior-season estimates without a statistically significant difference; Arexvy and Abrysvo estimates were similar, while mResvia lacked enough uptake for an estimate.
- FDA’s GBS warning for Abrysvo and Arexvy reflects a rare, unconfirmed signal; FDA says the benefits continue to outweigh the risks.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
Who should receive an adult RSV vaccine under current CDC guidance?
CDC recommends one dose for every adult aged 75 years or older and for adults aged 50–74 who are at increased risk of severe RSV illness.
What does the two-season evidence say about adult RSV vaccine protection?
One dose was associated with an estimated 58% effectiveness against RSV-associated hospitalization among adults aged 60 years or older in the IVY hospitalized surveillance study. The estimate was observational, with a 45%–68% confidence interval, and is not a personal forecast.
How do time and vaccine product affect adult RSV vaccination decisions?
Time raises an unresolved durability question, while product evidence is uneven rather than a basis for a universal ranking. Same-season effectiveness was estimated at 69% versus 48% after prior-season vaccination without a statistically significant difference; Arexvy and Abrysvo were similar, while mResvia lacked enough uptake for an estimate.
What does the GBS warning mean for adult RSV vaccination?
It means FDA found a possible increased risk of GBS within 42 days after Abrysvo or Arexvy, but the evidence was insufficient to establish causality. FDA estimates were about 9 and 7 excess cases per million doses, and says benefits continue to outweigh risks.